Allocetra™ is an innovative immunotherapy that is being developed to rebalance life-threatening hyperactivity of the immune system, using the immune system’s own natural regulation mechanisms. By intelligently engaging macrophages and dendritic cells, Allocetra™ is designed to avert cytokine storms and restores safe immune balance – without suppressing the immune system.
Location: Israel, Center District, Nes Ziona
Total raised: $13.2M
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.04.2019 | Pre-IPO | $5.2M | - |
| 25.09.2017 | - | $8M | - |
Mentions in press and media 24
| Date | Title | Description | Source |
| 13.12.2021 | Enlivex Receives Regulatory Authorization to Expand its Phas... | Nes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “C... | marketscre... |
| 13.12.2021 | Enlivex Therapeutics : Receives Regulatory Authorization to ... | Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Seve... | marketscre... |
| 07.12.2021 | Enlivex Receives Regulatory Authorization to Expand its Phas... | Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “C... | marketscre... |
| 07.12.2021 | Enlivex Therapeutics : Receives Regulatory Authorization to ... | Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece Nes-Ziona... | marketscre... |
| 06.12.2021 | Enlivex Receives Notice of Allowance for U.S. Patent Applica... | Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “C... | marketscre... |
| 06.12.2021 | Enlivex Therapeutics : Receives Notice of Allowance for U.S.... | Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis P... | marketscre... |
| 22.11.2021 | Enlivex Therapeutics : Initiated dosing in placebo-controlle... | Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and... | marketscre... |
| 22.11.2021 | Enlivex Announces Third Quarter 2021 Financial Results and P... | Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and... | marketscre... |
| 04.11.2021 | Spanish Regulator Grants Enlivex Authorization To Expand Its... | Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain Nes Ziona, ... | marketscre... |
| 04.11.2021 | Spanish Regulator Grants Enlivex Authorization To Expand Its... | Nes Ziona, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “C... | marketscre... |
Show more